Roche reported strong first-half results driven by demand for innovative medicines and diagnostics, with sales up 6% at constant exchange rates. The Pharmaceuticals Division saw growth from key drugs like Xolair, Hemlibra, and Ocrevus, while the Diagnostics Division benefited from increased demand for its products. Core operating profit rose 10% at constant exchange rates, though reported profits in Swiss francs were impacted by currency appreciation. Several drugs received US Priority Reviews for various cancers and autoimmune diseases, indicating significant pipeline progress. Positive Phase III data emerged for divarasib in lung cancer, and promising results were presented for other compounds in multiple sclerosis and obesity. The company also launched a new next-generation sequencing platform and received EU approval for Alzheimer's and tuberculosis tests. Acquisitions and collaborations, including a deal with Nurix Therapeutics and the planned purchase of PathAI, further bolster Roche's diagnostic capabilities. The company reaffirmed its 2026 outlook, expecting mid-single-digit sales growth and high-single-digit core earnings per share growth at constant exchange rates. This continued momentum positions Roche for sustained future growth and further dividend increases.